Drug Details

General Information of the Drug (ID: DR1806)
Name
Ivacaftor
Synonyms
Ivacaftor; 873054-44-5; VX-770; Kalydeco; Ivacaftor (VX-770); N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX 770; VX770; UNII-1Y740ILL1Z; N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; CHEBI:66901; 1Y740ILL1Z; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide; 3-Quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-; 3-Quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-; Kalydeco (TN); Ivacaftor [USAN:INN]; ivacaftorum; Ivacaftor D18; Tube715; Ivacaftor (USAN/INN); VX-770 - Ivacaftor; cc-231; MLS006011119; SCHEMBL351373; GTPL4342; QUI135; VX-770, Ivacaftor, Kalydeco; CHEMBL2010601; DTXSID00236281; EX-A441; QCR-155; BCPP000199; HMS3654E10; HMS3744K05; AOB31714; BCP19794; ABP000259; BDBM50032693; MFCD17171361; s1144; VX-770/VX770; ZINC52509463; AKOS015994762; AKOS032950001; BCP9000799; CCG-268562; CS-0497; DB08820; EX-7211; LE-0002; SB16815; N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; NCGC00242480-01; NCGC00242480-03; 1413431-05-6; AC-28324; AK170457; HY-13017; SMR004702900; AB0008116; FT-0696681; SW219620-1; X7565; EC-000.2478; A25626; D09916; W-5681; AB01565806_02; Q6095693; CTP-656; CTP-656; CTP-656; d9-ivacaftor;VX-561; Cystic Fibrosis Transmembrane Conductance Regulator Potentiator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide; N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; N-(5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide; 1134822-00-6; Kalydeco; ; ; N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide; VX7
    Click to Show/Hide
Molecular Type
Small molecule
Disease Cystic fibrosis [ICD-11: CA25] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 10600 mcgh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 768 mcg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Clearance
The clearance of drug is 17.3 L/h in healthy subjects
Elimination
After oral administration, ivacaftor is mainly eliminated in the feces after metabolic conversion and this elimination represents 87.8% of the dose
Half-life
The concentration or amount of drug in body reduced by one-half in 12 hours
Metabolism
The drug is metabolized via the CYP3A
Vd
The volume of distribution (Vd) of drug is 353 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C24H28N2O3
PubChem CID
16220172
Canonical SMILES
CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
InChI
1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
InChIKey
PURKAOJPTOLRMP-UHFFFAOYSA-N
CAS Number
CAS 873054-44-5
ChEBI ID
CHEBI:66901
TTD Drug ID
D0W7WC
DrugBank ID
DB08820
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Resveratrol      Gnetum parvifolium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Cells derived from cystic fibrosis patients Cystic fibrosis Homo sapiens
Fisher rat thyroid cells Healthy Rattus norvegicus
                    Experimental
                    Result(s)		 Additive improvement in G551D CFTR-mediated Cl-secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.
Target and Pathway
Target(s) Cyclic AMP-dependent chloride channel (CFTR)  Molecule Info  [3]
KEGG Pathway ABC transporters Click to Show/Hide
2 cAMP signaling pathway
3 AMPK signaling pathway
4 Gastric acid secretion
5 Pancreatic secretion
6 Bile secretion
7 Vibrio cholerae infection
Reactome ABC-family proteins mediated transport Click to Show/Hide
WikiPathways ABC-family proteins mediated transport Click to Show/Hide
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4342).
Reference 2 Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease. Int Forum Allergy Rhinol. 2019 Jan;9(1):100-105.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
 Download Picture         KEGG Link